文献速递中医内科中药与中成药合理使用

小青龙汤治疗过敏性鼻炎的系统评价与Meta分析

Efficacy and safety of the Chinese herbal medicine Xiao-qing-long-tang for allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · J Ethnopharmacol · 2022-03-04

该系统评价纳入24项随机对照试验,评估小青龙汤(XQLT)治疗过敏性鼻炎(AR)的有效性与安全性。Meta分析显示,XQLT单用或联合西药可降低总鼻症状评分(TNSS)、流涕和鼻塞评分,提高有效率并降低复发率,且耐受性良好。但研究的方法学质量有限,仍需更多严格设计的RCT验证。

要点

  • XQLT单用或联合西药可改善AR患者的TNSS、流涕和鼻塞症状。
  • XQLT及联合治疗的有效率高于西药,复发率低于西药。
  • XQLT耐受性良好,但纳入研究的方法学质量需提高。

核心结论

  • 口服小青龙汤可能减轻AR患者的TNSS、流涕和鼻塞评分,临床使用安全。

研究设计与样本

  • 系统评价与Meta分析,检索9个数据库至2021年4月,纳入24项RCT,使用Cochrane偏倚风险评估工具。

主要发现

  • 与安慰剂或西药相比,XQLT及联合治疗降低TNSS(MD -0.79,95%CI [-1.20, -0.38];SMD -1.42,95%CI [-1.59, -1.24];SMD -1.84,95%CI [-2.08, -1.60])。
  • XQLT及联合治疗改善流涕(SMD -0.30,95%CI [-0.58, -0.02];SMD -0.48,95%CI [-0.70, -0.26])和鼻塞(SMD -0.54,95%CI [-0.78, -0.30];SMD -0.54,95%CI [-0.76, -0.32])。
  • XQLT及联合治疗的有效率高于西药(RR 1.18,95%CI [1.11, 1.25];RR 1.16,95%CI [1.10, 1.23]),复发率低于西药(RR 0.24,95%CI [0.13, 0.43];RR 0.47,95%CI [0.31, 0.72])。
  • XQLT在AR患者中耐受性良好。

关键数值与推荐

  • 纳入24项RCT,比较XQLT与安慰剂、西药及XQLT联合西药与单用西药。
  • 主要结局包括TNSS、四个单项鼻症状评分、生活质量、有效率和复发率。

临床怎么用

  • 可考虑使用小青龙汤单用或联合西药治疗AR,以改善鼻部症状并降低复发。
  • 使用时应关注患者耐受性,并结合具体病情辨证论治。

局限性

  • 纳入研究的方法学质量有限,需要更多严格设计和采用公认结局指标的RCT验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: The classic Chinese herbal medicine formula Xiao-qing-long-tang (XQLT) is commonly recommended to manage allergic rhinitis (AR), but the treatment efficacy and safety of XQLT are uncertain. AIM OF THE STUDY: This study aimed to evaluate the effectiveness and safety of XQLT in treating AR. MATERIALS AND METHODS: Nine databases were searched from their inception to April 2021. Randomized controlled trials (RCTs) evaluating XQLT for AR were included. The methodological quality of the studies was assessed using the Cochrane risk-of-bias tool. A meta-analysis and a subgroup meta-analysis were conducted to evaluate the effectiveness of XQLT. RESULTS: Twenty-four RCTs were included in this meta-analysis. XQLT was compared to both placebo and Western medicine (WM), and XQLT combined with WM was compared with WM alone. Meta-analyses were conducted for total nasal symptom scores (TNSS), four individual nasal symptom scores, quality of life (QoL), effective rate, and recurrence rate. The TNSS decreased after XQLT treatment and combination treatment (mean difference (MD): -0.79; 95% confidence interval (CI) [-1.20, -0.38], standardized mean difference (SMD): -1.42; 95% CI [-1.59, -1.24], and SMD: -1.84; 95% CI [-2.08, -1.60]). The two individual nasal symptom scores decreased after XQLT treatment and combination treatment; these nasal symptoms comprised rhinorrhea (SMD: -0.30; 95% CI [-0.58, -0.02] and SMD: -0.48; 95% CI [-0.70, -0.26]), and nasal obstruction (SMD: -0.54; 95% CI [-0.78, -0.30] and SMD: -0.54; 95% CI [-0.76, -0.32). XQLT and XQLT combined with WM achieved a better effective rate than WM (risk ratio (RR): 1.18; 95% CI [1.11, 1.25] and RR: 1.16; 95% CI [1.10, 1.23]) and a lower recurrence rate than WM (RR: 0.24; 95% CI [0.13, 0.43] and RR: 0.47; 95% CI [0.31, 0.72]). XQLT was well tolerated in patients being treated for AR. CONCLUSION: Our results indicated that oral XQLT may alleviate the TNSS, rhinorrhea scores, and nasal obstruction scores of AR and is safe to use in clinical practice. However, more RCTs that follow rigorous methodologies and evaluate well-accepted outcome measures are required to evaluate the effectiveness of XQLT.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Yan Y, Zhang J, Liu H, et al. Efficacy and safety of the Chinese herbal medicine Xiao-qing-long-tang for allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials. J Ethnopharmacol. 2022. PMID: 35257842. doi:10.1016/j.jep.2022.115169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。